By Nate Raymond (Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

AG Ken Paxton pushed debunked misinformation about COVID-19 vaccines. What a shame the damage can’t be undone as easily as ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...